Objective: To summarize and evaluate immunotherapy agents targeting programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) recently approved for the treatment of metastatic urothelial carcinomas (UC). Data Sources: A literature review was performed using PubMed (2012 to June 2017), the American Society of Clinical Oncology abstract databases (2012 to June 2017 Annual Meetings/symposia), and the America Association for Cancer Research symposia (2012 to June 2017). A search using clinicaltrials.gov was conducted to identify studies for atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab. Study Selection and Data Extraction: English language phase I to III studies assessing PD-1 and PD-L1 in UC were incorporated. Data Synthesis: Atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab have demonstrated clinical efficacy with tolerable toxicities in patients with metastatic UC with disease progression following platinum-based chemotherapy. Anti-PD-1/PD-L1 therapies may provide overall survival advantage; these are currently being evaluated in ongoing phase 3 studies. Greater objective response rates seem to be observed in PD-L1-positive patients versus PD-L1-negative patients, but methodologies in this assessment differ among clinical trials. The identification of biomarkers that provide greater insight into patients who positively respond to PD-1/ PD-L1 therapies are needed. Conclusions: Treatment options for metastatic UC have expanded to include PD-1/PD-L1 therapies. These agents should be strongly considered as second-line therapy over single-agent chemotherapy for patients who fail or progress after platinum-based treatment.
Introduction
Urothelial carcinomas (UC) refer to a group of malignancies that affect the bladder, renal pelvis, ureter, and other urinary organs. In 2016, there were approximately 143,190 new cases and 31,540 estimated deaths from UC in the United States. 1 Despite this prevalence, there has been a lack of novel treatment options for approximately 3 decades. Currently, systemic platinum-based chemotherapy (PBCT) is the standard of care for patients with UC, with median overall survival (OS) around 14 months; however, many patients are either ineligible for or cannot tolerate the toxicities associated with PBCT. 2 Furthermore, there is a lack of recognized effective second-line therapies for patients who experience disease progression following PBCT, with no regimen having a significant OS advantage compared with best supportive care. 3, 4 Although immunotherapy was initially investigated more than 40 years ago in bladder cancer with the use of Bacillus Calmette-Guérin, other immune targeting agents have not been approved for UC until recently. 5, 6 The Food and Drug Administration (FDA) approvals of atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab as second-line therapies for locally advanced or metastatic disease represents a significant milestone in the treatment of UC. [7] [8] [9] [10] [11] In addition, atezolizumab and pembrolizumab have received FDA approval for frontline use in cisplatin-ineligible patients with locally advanced or metastatic UC. The emergence of novel immunotherapy agents in this clinical treatment setting provides promise for the future. The objective of this review is to summarize and evaluate immunotherapy agents targeting programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) recently approved for the treatment of metastatic UC.
Treatment Landscape for Urothelial Carcinomas
Bladder cancer is estimated to be the fifth most common cancer and the ninth leading cause of cancer death in the United States. It is most common in Caucasians and men, and the average age at diagnosis is approximately 73 years. 1 UC accounts for nearly 90% of all bladder cancers, with 25% of patients presenting with muscle-invasive or metastatic disease. 12 Cisplatin-based chemotherapy remains the standard of care as first-line treatment for locally advanced or metastatic UC, but many patients are not candidates for treatment due to renal impairment and other comorbidities. For those patients who receive standard first-line PBCT, OS is roughly 9 to 15 months; however, this is reduced to 5 to 7 months in patients who relapse. Single chemotherapeutic agents recommended for second-line use in advanced disease include paclitaxel, gemcitabine, and pemetrexed, although none have received FDA approval for this indication. 13 These agents have only been evaluated in phase II studies and have demonstrated modest overall response rates with considerable toxicities. [14] [15] [16] [17] Considering the high mortality in metastatic disease, there has been an unmet need of effective therapies with a favorable adverse event profile for this patient population.
Programmed Cell Death Protein-1 Immunotherapy
Over the past decade, there has been increasing interest in immune checkpoint inhibitors in the treatment of various malignancies. Immune checkpoints are crucial inhibitory pathways responsible for regulating immune response, primarily through modulation of T-cell activation. It is now established that various immune checkpoint molecules are overexpressed by tumor cells (TCs), allowing them to evade immune attack. 18 One of these checkpoints is the PD-1 pathway. PD-1 is a cell-surface molecule that is activated by 2 ligands: PD-L1 and PD-L2. 19 PD-L1 is widely expressed on a multitude of immune cells (ICs) and may be upregulated on TCs. 20 The binding of PD-L1 to PD-1 receptors provides an inhibitory signal to T cells, suppressing their migration, proliferation, and release of cytotoxic mediators. This ultimately results in downregulation of the immune response against the tumor.
21 By inhibiting the interaction between PD-1 and PD-L1, antitumor immunity is preserved, which has been a potent therapeutic strategy for cancer treatment. 18 PD-1-targeting immunotherapy has emerged as an effective option for malignancies such as advanced melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, and classical Hodgkin lymphoma. 22 Interestingly, malignancies associated with higher PD-L1 tumor expression and those with a higher burden of somatic mutations have been identified to respond well to immune checkpoint inhibitors. 23 Data from the Cancer Genome Atlas reports that bladder cancer has the third highest rate of mutations behind lung cancer and melanoma. 24 This suggests the PD-1-and PD-L1-targeting immunotherapy may be an effective treatment option for bladder cancer. A search using clinicaltrials.gov was conducted to identify pertinent studies, and additional online searches were performed for guidelines and prescribing information. References cited in the identified studies, review articles, and guidelines were screened for inclusion. Articles were included in the review if they reported clinical trial data with traditional chemotherapy or immunotherapeutic agents in the treatment of bladder cancer. Case reports were excluded from this review.
Data Sources
A total of 89 articles were identified and screened against inclusion and exclusion criteria; 15 clinical trials were included in this review. We used the Cochrane risk-of-bias assessment to examine bias in randomized clinical trials (RCTs). The following criteria were evaluated: (1) randomized sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other sources of bias. Each domain was evaluated independently by investigators as yes, no, or unclear. A summary of pertinent clinical trials is outlined in Table 1 .
PD-L1 Inhibitors: Evaluation of Clinical Efficacy and Safety

Atezolizumab
Atezolizumab is a humanized monoclonal immunoglobulin-G1 (IgG1) antibody that targets PD-L1 found on TCs and tumor-infiltrating ICs. 25, 26 As an IgG1 isotype, atezolizumab has an engineered crystallizable fragment (Fc) domain modification designed to eliminate antibody-dependent cell-mediated cytotoxicity (ADCC). This was done to 
weeks Advanced UC with progression following PBCT 542 21% Pembrolizumab vs 11.4% chemotherapy (P = 0.001) prevent any potential toxicity from ADCC-mediated lysis of ICs expressing PD-L1. 27, 28 Atezolizumab was granted accelerated approval by the FDA in May 2016 for patients with locally advanced or metastatic UC with disease progression during or following PBCT or within 12 months of neoadjuvant or adjuvant chemotherapy. In April 2017, it received an additional accelerated approval for patients not eligible to receive cisplatin-containing chemotherapy. Atezolizumab is also approved for use in metastatic nonsmall cell lung cancer. 8 Phase I studies of atezolizumab identified that a 15-mg/ kg/dose, or fixed-dose equivalent of 1200 mg, administered every 3 weeks was sufficient in maintaining necessary concentrations to provide target saturation. Further pharmacokinetic simulations found no clinically meaningful differences between the fixed versus weight-based dosing; therefore, a fixed dose of 1200 mg (equivalent to 15 mg/kg based on an average body weight of 80 kg) was selected for subsequent studies. 25 The IMvigor 210 trial was an open-label, multicenter, single-arm phase II study (n = 310) that evaluated the safety and efficacy of atezolizumab in patients with locally advanced or metastatic UC. Patients were enrolled in 2 cohorts: cohort 1 consisted of those who received no prior therapies and were ineligible for PBCT, and cohort 2 included patients who experienced disease progression following PBCT. Study participants received 1200 mg intravenous (IV) atezolizumab every 3 weeks on day 1 until loss of clinical benefit. Patient tumor samples were assessed for PD-1 expression with an investigational immunohistochemistry test. The PD-L1 tumor-infiltrating IC status was the percentage of PD-L1-positive ICs in the tumor microenvironment. Patients were grouped according to percentage of PD-L1 expression as follows: IC0 (<1%), IC1 (1%-4%), and IC2/3 (≥5%). These groups were evenly matched in both cohorts.
Rosenberg et al 29 reported the data from cohort 2. The primary objective for the study was objective response rate (ORR) according to RECIST (Response Evaluation Criteria in Solid Tumors) compared with a historical 10% response rate. At primary analysis, the ORR was 15% (11-20; P = 0.0058) for all patients, and for subgroups IC2/3, IC1/2/3, and IC0, the ORRs were 27%, 18%, and 8%, respectively. The median OS was 7.9 months for the entire cohort and was improved in the IC2/3 group (11.4 months) as compared with the IC1/2/3 and IC0 groups (8.8 and 6.5 months, respectively). Additionally, 11 of the 15 patients who experienced a complete response were in the IC2/3 group. Median progression-free survival (PFS) was comparable among all IC groups. With a higher ORR and median OS in the IC2/3 group, these results reinforce the correlation of PD-L1 expression with treatment response found in the phase I PCD4989g trial. 30 Interestingly, an exploratory translational analysis showed that the median mutational load was significantly increased in responders when compared with nonresponders (12.4 vs 6.4 per megabase, P < 0.0001), supporting the association between mutational load and immunotherapy response. Additionally, greater responses to atezolizumab were associated with high expressions of chemokine ligand 9 (CXCL9; P = 0.0057) and 10 (CXCL10; P = 0.0079) as well as tumors with high CD8+ infiltration (P = 0.0265). 29, 31 Balar et al 32 reported results from the cisplatin-ineligible study (cohort 1). The primary endpoint was ORR according to RECIST criteria and was 23% in all patients. Unlike cohort 2, ORR was similar across all subgroups (28%, 24%, and 21% for IC2/3, IC1/2/3, and IC0, respectively), and median OS was lower in the IC2/3 patients as compared with IC0/1 patients (12.3 vs 19.1 months, respectively). Larger studies will need to confirm the OS results seen in both cohorts of the IMvigor 210 study because it was not adequately powered for that endpoint.
Ongoing phase 3 studies (IMvigor211 and IMvigor130) will continue to evaluate clinical response in relation to PD-L1 expression as well as mutational load. The IMvigor 211 trial included 931 patients with previously treated metastatic UC who progressed on or after PBCT and was intended to confirm the results seen in the IMvigor 210 study. However, a recently released report indicated that atezolizumab failed to meet the primary endpoint of improvement in OS. 33 Full results from the study are expected to be presented later this year.
Atezolizumab seems to have a more favorable safety profile compared with chemotherapy; this is encouraging when considering that many patients with metastatic disease decide against receiving second-line treatment due to toxicity concerns. 34 In cohort 2 of the IMvigor210 study, 69% of the 310 patients experienced any grade treatmentrelated adverse event (TRAE), 11% had grade 3/4, with fatigue being most common. The incidence of immunemediated adverse events (imAEs) was low (7%) and included pneumonitis, increased hepatic transaminases, rash, and dyspnea; however, 15 of the 23 patients (65%) who experienced an imAE had grade 3/4 events. Also, 11 patients (4%) withdrew treatment because of TRAEs, and 22% required treatment with systemic steroids. 29 Rates of TRAEs were similar in cohort 1 of the IMvigor210 study; however, 1 patient died from sepsis, which was determined to be treatment related. Of the 12% of imAEs, 7% were grade 3/4; systemic steroids were necessitated in 36 (30%) patients. 32 
Durvalumab
Durvalumab is a highly selective IgG1 monoclonal antibody that blocks PD-L1. On May 1, 2017, it received FDA accelerated approval for patients with locally advanced or metastatic UC with disease progression during or following PBCT or within 12 months of neoadjuvant or adjuvant PBCT. Durvalumab is not currently approved for other malignancies. 9 A phase I/II multicenter, open-label, dose escalation and dose expansion study was conducted with durvalumab (10 mg/kg IV every 2 weeks) in advanced UC patients (n = 61). The majority of patients (93.4%) had received 1 or more prior lines of systemic therapy, including 31% who had received 3 or more. A biomarker analysis evaluating PD-L1 expression on TCs or ICs was performed in an attempt to identify subsets of patients who were more likely to respond to PD-1 therapy. Tumor tissues were assessed by immunohistochemistry using an analytically validated assay for a percentage of cells expressing PD-L1 above background staining. PD-L1 status was defined as positive if either ≥25% of TCs or ICs expressed PD-L1 and negative if <25% of TCs and ICs expressed PD-L1. This cutoff was selected based on previous studies with durvalumab in other solid tumors. Durvalumab was administered for 12 months or until confirmed progression of disease or unacceptable toxicity. The primary endpoint was safety assessment; secondary endpoints included ORR and disease control rate (DCR) at 12 weeks according to RECIST criteria. DCR was defined as complete response, partial response, or stable disease for ≥12 weeks. 35, 36 Of the 42 response-evaluable patients, the ORR was 31%; however, it was 0% in PD-L1-negative patients. DCR was higher in the PD-L1-positive subgroup as compared with the PD-L1-negative subgroup (57.1% vs 28.6%). Antitumor activity demonstrated in PD-L1-positive patients was particularly noted in reduction of tumor size: 68% of PD-L1-positive patients had a ≥30% reduction from baseline, as compared with only 9% in PD-L1-negative patients. When evaluating IC status, the ORR was improved in PD-L1-positive compared with PD-L1-negative status (55.6% vs 12.5%). Similarly, TC-only status reported increased ORR for patients who were PD-L1 positive (46.7%) compared with patients who were PD-L1 negative (22.2%). 35 These findings suggest that PD-L1 expression on either TCs or ICs may be useful in determining PD-L1 status and is a biomarker of interest in the determination of responders.
Updated results from the phase I/II study were presented at the 2017 American Society of Clinical Oncology Annual Meeting. For the 191 patients enrolled, the ORR was 17.8%. In those with PD-L1-positive disease (n = 98), the ORR was 27.6%, which included 4 complete responses and 23 partial responses. In those with PD-L1-negative disease (n = 79), the ORR was 5.1%. The median PFS and OS for all patients were 1.5 and 18.2 months, respectively. Grade 3/4 TRAEs were reported in 6.8% of patients and consisted of infusion-related reactions, tumor flare, and acute kidney injury. Grade 3/4 imAEs occurred in 4 patients, and 2 patients discontinued treatment because of imAEs (acute kidney injury and autoimmune hepatitis). 37 
Avelumab
Avelumab is a fully human IgG1 monoclonal antibody that differs from other anti-PD-L1 agents in that it has the potential to induce ADCC. Whereas atezolizumab has a specially engineered Fc-domain to prevent ADCC, avelumab retains a native F c region and has shown in vitro activity to induce lysis of TCs, but not human ICs. 28 On May 9, 2017, the US FDA granted accelerated approval to avelumab in patients with locally advanced or metastatic UC whose disease progressed during or following PBCT or within 12 months of neoadjuvant or adjuvant PBCT. Avelumab is also approved for metastatic Merkel cell carcinoma. 10 Accelerated approval was based on data from the UC cohorts (n = 44) in the single arm, open-label, multicenter JAVELIN Solid Tumor trial. The primary objective of this study was to assess safety and tolerability; secondary objectives included ORR, PFS, OS, and PD-L1-associated clinical activity. PD-L1 expression was defined as expression on ≥5% of TCs by immunohistochemistry using a proprietary assay. Of the 37 patients evaluable for PD-L1 expression, 13 were considered PD-L1 positive and 24 were PD-L1 negative. Avelumab was administered at 10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity. The ORR was 18.2% (95% CI = 8.2-32.7) in all patients, 53.8% in PD-L1-positive patients, and 4.2% in PD-L1-negative patients. Additionally, 7 of the 8 responders were PD-L1 positive. Furthermore, there was greater median OS and PFS in the PD-L1-positive group than the PD-L1-negative group (not reached vs 12.9 months and 48.1 vs 7.1 weeks, respectively). 38 An update to this study was presented at the 2017 ASCO Genitourinary Cancer Symposium. Data were presented on 161 patients who had at least ≥6 months of follow-up. Confirmed ORR was 17.4% in all patients, with a complete response in 10 patients. Based on ≥5% PD-L1 staining on TCs, ORRs were increased in the PD-L1-positive subgroup versus PD-L1-negative subgroup (25.4% vs 13.2%). In all patients, median PFS was 6.6 weeks, and the median OS was 7.4 months. Avelumab is currently being evaluated in a phase III trial (JAVELIN Bladder 100) as maintenance therapy for patients with locally advanced or metastatic UC who have not progressed following PBCT.
TRAE of any grade occurred in 66.7%, with infusionrelated reactions (22.9%) and fatigue (16.1%) being the most common. Grade 3/4 TRAEs occurred in 8.4% of patients, which consisted primarily of fatigue (1.6%) and asthenia (0.8%). In all, 34 patients (13.7%) experienced an imAE, with 2.4% being grade 3 or higher. There was 1 treatment-related death caused by pneumonitis.
PD-1 Inhibitors: Evaluation of Clinical Efficacy and Safety
Nivolumab
Nivolumab is a humanized monoclonal IgG4 antibody that blocks PD-1 and is approved in advanced melanoma, metastatic non-small cell lung cancer, recurrent or metastatic head and neck cancer, advanced renal cell carcinoma, and classical Hodgkin lymphoma. As an IgG4 isotype, it does not mediate ADCC activity. Nivolumab was granted accelerated approval by the FDA in February 2017 for the treatment of patients with locally advanced or metastatic UC with disease progression during or following PBCT or within 12 months of neoadjuvant or adjuvant PBCT. 7 The safety and efficacy of nivolumab in metastatic UC was investigated in the nonrandomized, single-arm, openlabel phase 1/2 CheckMate 032 trial. The UC cohort (n = 78) received nivolumab 3 mg/kg IV every 2 weeks until disease progression or treatment discontinuation for unacceptable toxicity. All patients had received 1 or more prior lines of therapy, although 3 patients (4%) had refused standard therapy with PBCT. Tumor PD-L1 expression was assessed using a validated immunohistochemical kit and was considered positive if expressed on ≥1% of TCs. Of the 67 assessable patients, 63% had <1% PD-L1 expression, 16% had 1% to 4% PD-L1 expression, and 21% had ≥5% PD-L1 expression. The primary endpoint was ORR, with PFS and OS included as secondary outcomes. For all patients, the ORR was 25.7%, median OS was 9.7 months, and median PFS was 2.8 months. When comparing responses between subgroups, there was greater median OS and PFS in PD-L1-positive than PD-L1-negative patients (16.2 vs 9.9 months and 5.5 vs 2.8 months, respectively). However, there was a similar rate of objective response between the 2 groups (24% in PD-L1 ≥1% and 26% in PD-L1 <1%). 40 The CheckMate 275 was a multicenter phase 2 trial that evaluated nivolumab in patients with metastatic or surgically unresectable UC with disease recurrence or progression following PBCT. The same dosing regimen used in CheckMate 032 was administered and evaluated in 265 patients. PD-L1 status was defined in the same manner as the CheckMate 032 trial; 54% had PD-L1 <1%, and 46% had PD-L1 ≥1%. The primary endpoint, ORR, was 19.6% for all patients, and the rates were comparable despite PD-L1 expression (56% for PD-L1 ≥1%, 44% for PD-L1 <1%). Consistent with the CheckMate 032 study, the median OS was increased in patients with PD-L1 expression of ≥1% versus <1% (11.3 and 5.95 months, respectively). Interestingly, investigators of the CheckMate 275 performed 177 high-quality gene expression profiles on patient tumor samples. Patients with high interferon-γ gene expression as well as tumors enriched with CXCL9, CXCL10, CD8, and 12-chemokine signature responded better to nivolumab. 41 These findings, along with those seen in the IMvigor 210 trial, represent an intriguing finding in immune checkpoint inhibition and potential biomarkers in the identification of responders. This association will continue to be elucidated in future studies.
Grade 3/4 TRAEs occurred in 22% of patients in the CheckMate 032 trial. The most commonly reported events consisted of elevated lipase and amylase levels, fatigue, decreased lymphocyte and neutrophil counts, maculopapular rash, and dyspnea. Immune-related adverse events were primarily skin (42%), gastrointestinal (10%), renal (9%), hepatic (5%), and pulmonary (3%) related; most of these were managed with steroids. Two patients died as a result of TRAEs (pneumonitis and thrombocytopenia). 40 A similar occurrence of grade 3/4 TRAEs was seen in the CheckMate 275 trial (18%); these were primarily fatigue and diarrhea. Three patients died from TRAEs, which included pneumonitis, acute respiratory failure, and cardiovascular failure. The most common imAEs were skin and endocrine related (17% and 14%, respectively). 41 Similar to atezolizumab, nivolumab utilizes a flat dose of 240 mg IV every 2 weeks, or the equivalent of 3 mg/kg, using an average body weight of 80 kg. No clinically significant differences were found in terms of safety or efficacy between the 2 dosing strategies. 42 
Pembrolizumab
Pembrolizumab is a humanized monoclonal IgG4, which is FDA approved in advanced melanoma, advanced nonsmall-cell lung cancer, recurrent head and neck squamous cell cancer, classical Hodgkin lymphoma, and UC. Recently, pembrolizumab was granted accelerated approval for the treatment of patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors who have progressed on previous treatment. To date, pembrolizumab is the only PD-1/PD-L1 agent that has received full FDA approval for patients with locally advanced or metastatic UC with disease progression following PBCT or within 12 months of adjuvant or neoadjuvant PBC. This was granted on May 18, 2017, along with accelerated approval for use in cisplatin-ineligible patients.
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The KEYNOTE-045 was an open-label, international, nonblinded, phase 3 trial, which randomized 542 patients to pembrolizumab (200 mg IV every 3 weeks) or investigator's choice of chemotherapy that consisted of paclitaxel, docetaxel, or vinflunine in patients with metastatic UC who progressed after PBCT. Treatment was continued until disease progression according to RECIST or unacceptable toxicity. The primary endpoints were both OS and PFS. A total of 164 patients had PD-L1 expression ≥10% (pembrolizumab, n = 74; chemotherapy, n = 90) that was defined using a PD-L1 combined positive score (CPS), which consists of TCs and ICs. The median OS in the whole study population was significantly improved in the pembrolizumab cohort (10.3 vs 7.4 months; HR = 0.70; P < 0.001). Specifically in those patients who had tumor PD-L1 expression ≥10%, OS favored the pembrolizumab cohort as well (8 vs 5.2 months; HR = 0.57; P = 0.005). However, pembrolizumab demonstrated a modest benefit over chemotherapy in patients with PD-L1 <1% but lacked statistical significance. Whereas median PFS for all patients was similar between the pembrolizumab and chemotherapy groups (2.1 vs 3.3 months), the ORR was nearly doubled in those receiving pembrolizumab (21.1% vs 11.0%). Furthermore, this response continued for ≥12 months in 69% of patients in the pembrolizumab group and only 36% in the chemotherapy group. 43, 44 The open-label, multicenter, phase II KEYNOTE-052 trial investigated pembrolizumab as a frontline treatment in platinum-ineligible patients. The study (n = 370) evaluated pembrolizumab (200 mg IV every 3 weeks) for safety and efficacy in PBCT-ineligible patients (Eastern Cooperative Oncology Group [ECOG] performance status >2, creatinine clearance <60 mL/min, ≥grade 2 neuropathy, New York Heart Association class III heart failure). The median age of the study population was 75 years (13% ≥85 years). Preliminary data were presented at the 2017 ASCO Annual Meeting. The primary objective of the study was ORR in all patients and in PD-L1+ patients by CPS. With a median 8-month follow-up, the ORR was 24% in all patients and was improved in patients with CPS ≥10% (47%). The median duration of response has not been reached (range = 1+ to 18+ months). 45 Given the estimation that approximately 30% to 50% of patients with advanced UC may not be candidates for PBCT, pembrolizumab may represent a treatment paradigm shift in this vulnerable patient population, providing antitumor activity with a tolerable adverse event profile.
Overall grade 3/4 TRAEs in the KEYNOTE-045 trial were more common in the chemotherapy arm (49.8% vs 16.5%). Typical chemotherapy-associated TRAEs were identified in >90% of patients, which consisted of anemia, neutropenia, alopecia, fatigue, and peripheral neuropathy. Pembrolizumab-associated toxicities were identified in 61.3% of patients and most commonly were pruritis, fatigue, and nausea. The treatment-related discontinuation rate was more common in the chemotherapy arm (11% vs 5.6%). The incidence of imAEs was 16.9%; pneumonitis, colitis, and nephritis were the most frequent grade 3/4 imAEs. In both treatment groups, 4 patients died as a result of TRAEs. In the pembrolizumab arm, these included pneumonitis (n = 1), urinary tract obstruction (n = 1), malignant neoplasm progression (n = 1), and 1 unspecified case (n = 1). 43 The toxicity profile in the predominantly elderly population of the KEYNOTE-052 study was similar to the KEYNOTE-045; 65% experienced any grade TRAE, with 18% being grade 3/4. Immune-mediated adverse events occurred in 21% of patients. 45 
Risk of Bias Assessment Summary
Many of the studies evaluated in this review were openlabel, single-arm trials that have a high risk of selection, performance, and detection bias. At the time of this review, the IMvigor211 phase III study has not been published to evaluate risk of bias. Thus, the only RCT that could be formally evaluated for bias in this review was the KEYNOTE-045. There was a lack of discussion on the generation of randomization sequence, which may lead to selection bias. Also, given the open-label design of the trial, the probability of performance and detection bias was high. The use of an external data and safety monitoring, which assessed efficacy and safety, may reduce these biases. Attrition bias was low; the primary reason for discontinuation of treatment in both arms was disease progression. Reporting bias was unclear; potential involvement of the sponsor in the study design and analysis was another potential bias identified.
Discussion
The first approval of an anti-PD-1 agent in May 2016 ignited a significant change in the treatment of metastatic UC, a setting that had previously remained static for more than 3 decades. The ensuing emergence of 4 additional agents for patients who have progressed on or following PBCT has provided a plethora of treatment options for this population. There is no doubt that these PD-1/PD-L1 inhibitors demonstrate similar, if not greater, efficacy over other second-line agents. A recent meta-analysis of 22 clinical trials evaluating single-agent second-line therapies for metastatic UC reported a median OS of 6.9 months; in comparison, the median OS for PD-1/PD-L1 inhibitors ranged from 7.4 to 18.2 months. 46 As frontline therapy for cisplatin-ineligible patients, median OS was 9.3 months in a study of cisplatin-ineligible, treatment-naive patients receiving gemcitabine/carboplatin. 47 Atezolizumab demonstrated an OS of 15.9 months; this data has yet to be reported for pembrolizumab.
Many questions still remain as to which of these treatments is superior and in which patients they will be most efficacious. Most of the aforementioned studies showed a greater response in patients who were PD-L1 positive; however, thresholds varied greatly among each study as well as methods for defining PD-L1 expression. For example, atezolizumab studies determined PD-L1 expression using ICs, whereas avelumab assessed TCs, and pembrolizumab assessed combined ICs and TCs. Additionally, a variety of immunohistochemistry assays were utilized, which could result in variability of PD-L1 measurements. Standardization of metrics and procedures for defining PD-L1 status could be helpful in optimizing decisions for immunotherapy treatment.
Pembrolizumab is currently the only available agent with mature phase III data demonstrating improved OS as well as a more favorable toxicity profile compared with chemotherapy. The National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer has also listed pembrolizumab as the only category 1 recommendation for subsequent systemic therapy for locally advanced or metastatic disease following PBCT. 13 Concerning cisplatin-ineligible patients in the front-line treatment setting, the NCCN Guidelines currently recommends both atezolizumab and pembrolizumab. Clinical trial data will continue to emerge evaluating PD-1/PD-L1 therapies in this population.
Conclusions
Novel therapies that are highly effective in the treatment of metastatic UC have been sought for decades. The use of PBCT or other systemic therapies have improved survival, but the selection of these agents in a patient population with multiple comorbidities is a challenge. Furthermore, toxicities associated with PBCT, including nephrotoxicity, myelosuppression, and significant emesis, are not well tolerated and may preclude its use in nearly 50% of patients. The recent emergence of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated promising efficacy in the treatment of metastatic UC, as both first-line therapy for cisplatin-ineligible patients and those who have disease progression following PBCT. The improved tolerability of these agents is very attractive; however, these agents provide their own challenges such as managing imAEs.
Whereas these agents have promising phase 2 data, which have led to accelerated approvals, critical phase 3 data are beginning to emerge. Will these agents continue to be utilized on a second-line setting or will they emerge as a frontline option in more than just platinum-ineligible patients? Additionally, identifying which patients will respond best to checkpoint inhibitors through PD-1/PD-L1 expression assays or other biomarker identification will provide greater insight into the role of immunotherapy in metastatic UC. Finally, questions remain concerning the utility of these agents after failing other immunotherapy agents. All the previously discussed trials excluded patients who had previously received immunomodulatory drug treatment. As the use of these therapies continues to increase, studies will be needed to address the possibility of sequential immunotherapy treatment. Given their favorable toxicity profile, anti-PD-1/PD-L1 agents are being evaluated in combination with chemotherapy as well as other checkpoint inhibitors, such as CTLA-4 inhibitors (ipilimumab) and indoleamine 2,3-dioxygenase inhibitors. With 5 recently FDA-approved therapies and numerous ongoing studies, immunotherapy may shape the future landscape of bladder cancer treatment.
